Syros Pharmaceuticals (0LC7) Ratios
Syros Pharmaceuticals Ratios
GB:0LC7's free cash flow for Q3 2024 was $-20.69M. For the 2024 fiscal year, GB:0LC7's free cash flow was increased by $0.00 and operating cash flow was $-20.69M. See a summary of the company’s cash flow.
| Ratios | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.95 | 6.87 | 4.33 | 6.24 | 4.87 |
| Quick Ratio | 3.95 | 6.87 | 4.33 | 6.24 | 4.86 |
| Cash Ratio | 3.80 | 5.44 | 2.93 | 6.08 | 1.76 |
| Solvency Ratio | -1.07 | -0.79 | -0.85 | -0.66 | -1.03 |
| Operating Cash Flow Ratio | -2.99 | -4.00 | -3.16 | -2.00 | -2.56 |
| Short-Term Operating Cash Flow Coverage | -16.46 | 0.00 | 0.00 | -33.20 | -47.15 |
| Net Current Asset Value | $ -6.53M | $ 94.64M | $ 38.87M | $ 55.86M | $ 43.72M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.37 | 0.26 | 0.36 | 0.31 | 0.17 |
| Debt-to-Equity Ratio | 3.73 | 0.50 | 0.76 | 0.73 | 0.33 |
| Debt-to-Capital Ratio | 0.79 | 0.33 | 0.43 | 0.42 | 0.25 |
| Long-Term Debt-to-Capital Ratio | 0.67 | 0.24 | 0.32 | 0.30 | 0.00 |
| Financial Leverage Ratio | 10.09 | 1.91 | 2.15 | 2.35 | 1.89 |
| Debt Service Coverage Ratio | -13.33 | -21.18 | -20.38 | -22.50 | -56.90 |
| Interest Coverage Ratio | -25.16 | -32.87 | -25.45 | -45.92 | 0.00 |
| Debt to Market Cap | 0.19 | 0.90 | 0.20 | 0.08 | 0.00 |
| Interest Debt Per Share | 2.37 | 5.36 | 11.05 | 14.77 | 6.44 |
| Net Debt to EBITDA | 0.49 | 1.19 | 0.34 | 1.36 | 0.21 |
| Profitability Margins | |||||
| Gross Profit Margin | 77.33% | 80.06% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -1604.74% | -608.33% | -351.89% | -544.93% | -3806.16% |
| EBITDA Margin | -1582.08% | -588.39% | -339.04% | -524.82% | -3668.82% |
| Operating Profit Margin | -1298.19% | -913.13% | -423.28% | -545.27% | -3922.35% |
| Pretax Profit Margin | -1656.34% | -636.12% | -368.52% | -556.80% | -3806.16% |
| Net Profit Margin | -1656.34% | -636.12% | -368.52% | -556.80% | -3806.16% |
| Continuous Operations Profit Margin | -1656.34% | -636.12% | -368.52% | -556.80% | -3806.16% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 127.59% | 69.66% | 87.06% | 102.12% | 97.04% |
| Return on Assets (ROA) | -97.86% | -38.72% | -47.32% | -39.41% | -50.30% |
| Return on Equity (ROE) | -987.72% | -74.10% | -101.57% | -92.81% | -95.27% |
| Return on Capital Employed (ROCE) | -98.09% | -63.58% | -65.66% | -44.57% | -61.47% |
| Return on Invested Capital (ROIC) | -91.82% | -62.97% | -64.79% | -43.76% | -60.26% |
| Return on Tangible Assets | -97.86% | -38.72% | -47.32% | -39.41% | -50.30% |
| Earnings Yield | -74.58% | -208.72% | -42.46% | -16.82% | -27.14% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 8.78 | 7.88 | 6.47 | 0.10 |
| Payables Turnover | 0.20 | 0.46 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.51 | 0.60 | 0.86 | 0.51 | 0.06 |
| Asset Turnover | 0.06 | 0.06 | 0.13 | 0.07 | 0.01 |
| Working Capital Turnover Ratio | 0.07 | 0.10 | 0.18 | 0.13 | 0.02 |
| Cash Conversion Cycle | -1871.03 | -747.13 | 46.29 | 56.37 | 3712.25 |
| Days of Sales Outstanding | 0.00 | 41.55 | 46.29 | 56.37 | 3712.25 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 1871.03 | 788.68 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 41.55 | 46.29 | 56.37 | 3712.25 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.87 | -9.74 | -15.92 | -12.46 | -14.98 |
| Free Cash Flow Per Share | -3.88 | -9.84 | -16.12 | -13.18 | -18.12 |
| Dividend Paid and CapEx Coverage Ratio | -403.33 | -99.17 | -79.95 | -17.20 | -4.77 |
| Capital Expenditure Coverage Ratio | -403.33 | -99.17 | -79.95 | -17.20 | -4.77 |
| Operating Cash Flow Coverage Ratio | -1.77 | -1.94 | -1.53 | -0.87 | -2.32 |
| Operating Cash Flow to Sales Ratio | -11.04 | -8.27 | -4.24 | -3.80 | -30.40 |
| Free Cash Flow Yield | -49.84% | -274.11% | -49.44% | -12.15% | -26.23% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.34 | -0.48 | -2.36 | -5.95 | -3.68 |
| Price-to-Sales (P/S) Ratio | 22.21 | 3.05 | 8.68 | 33.11 | 140.23 |
| Price-to-Book (P/B) Ratio | 13.24 | 0.36 | 2.39 | 5.52 | 3.51 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.01 | -0.36 | -2.02 | -8.23 | -3.81 |
| Price-to-Operating Cash Flow Ratio | -2.01 | -0.37 | -2.05 | -8.71 | -4.61 |
| Price-to-Earnings Growth (PEG) Ratio | 0.06 | 0.01 | 0.10 | 2.19 | 2.27 |
| Enterprise Value Multiple | -0.91 | 0.67 | -2.22 | -4.95 | -3.61 |
| Enterprise Value | 143.21M | -58.55M | 176.75M | 391.89M | 262.41M |
| EV to EBITDA | -0.91 | 0.67 | -2.22 | -4.95 | -3.61 |
| EV to Sales | 14.41 | -3.93 | 7.53 | 25.96 | 132.40 |
| EV to Free Cash Flow | -1.30 | 0.47 | -1.75 | -6.46 | -3.60 |
| EV to Operating Cash Flow | -1.31 | 0.48 | -1.78 | -6.83 | -4.36 |
| Tangible Book Value Per Share | 0.59 | 10.11 | 13.63 | 19.66 | 19.69 |
| Shareholders’ Equity Per Share | 0.59 | 10.11 | 13.63 | 19.66 | 19.69 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.35 | 1.18 | 3.76 | 3.28 | 0.49 |
| Net Income Per Share | -5.81 | -7.49 | -13.84 | -18.25 | -18.76 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.03 | 1.05 | 1.05 | 1.02 | 1.00 |
| Research & Development to Revenue | 10.88 | 7.52 | 4.25 | 5.04 | 29.39 |
| SG&A to Revenue | 2.85 | 1.97 | 0.98 | 1.41 | 10.84 |
| Stock-Based Compensation to Revenue | 1.05 | 0.77 | 0.44 | 0.72 | 4.96 |
| Income Quality | 0.67 | 1.30 | 1.15 | 0.68 | 0.80 |
Currency in USD